Arch Therapeutics, Inc.
ARTHOTCHealthcare
$0.00
+$0.00(+0.00%)
Market Cap$444
P/E Ratio—
52W High$1.567
52W Low$0.0001
Arch Therapeutics, Inc. (ARTH) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ARTH · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2023-09 | 2022-09 | 2021-09 | 2020-09 | 2019-09 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.08M | $0.02M | $0.01M | $0.00M | $0.00M |
| Cost of Revenue | $0.08M | $0.05M | $0.03M | $0.01M | $0.01M |
| Gross Profit | ($0.00M) | ($0.04M) | ($0.01M) | ($0.01M) | ($0.01M) |
| Gross Margin %(computed) | -3.22% | -228.96% | -127.25% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.67M | $1.15M | $1.35M | $1.61M | $2.40M |
| G&A Expenses | $4.37M | $4.52M | $5.01M | $3.76M | $3.97M |
| Total Operating Expenses | $5.04M | $5.67M | $6.36M | $5.37M | $6.37M |
| Operating Income | ($5.04M) | ($5.71M) | ($6.38M) | ($5.37M) | ($6.37M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.02M | $0.00M |
| Interest Expense | $3.10M | $0.57M | $0.15M | $0.02M | $0.00M |
| Income Before Tax | ($6.98M) | ($5.28M) | ($6.24M) | ($4.69M) | ($4.55M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($6.98M) | ($4.28M) | ($6.57M) | ($4.01M) | ($2.72M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.27 | $-3.56 | $-5.97 | $-4.27 | $-3.27 |
| Wtd Avg Shares | 3.07M | 1.20M | 1.10M | 0.94M | 0.83M |
| EBITDA | ($3.88M) | ($4.71M) | ($6.09M) | ($5.35M) | ($6.36M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Arch Therapeutics, Inc. data
About Arch Therapeutics, Inc. (ARTH) Income Statement
Arch Therapeutics, Inc. (ARTH) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2023, ARTH reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -3.22%), and net income of ($0.01B) — a net profit margin of -9221.43%.
Frequently asked questions
ARTH · 4 questionsArch Therapeutics, Inc. (ARTH) reported revenue of $0.00B for 2023, up 383.8% year-over-year.
ARTH revenueARTH salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09